CDK4 and colorectal cancer: We next studied the effect of CDK4/6 and GLS1 inhibitors alone and in constant ratio (1:4) combinations on the viability of HCT116 colorectal cancer and MCF‐7 and SK‐BR‐3 breast cancer cells (Fig 7A, see also Table EV4).